Patient safety is at the forefront of health care and nursing practice. Oncology nurses strive to provide safe oncologic care in their management of cancer, treatments, and side effects. Oncologic emergencies such as tumor lysis syndrome (TLS), however, are serious complications of cancer and cancer treatment. TLS often is seen in hematologic malignancies, such as lymphomas and leukemias, that frequently occur in older adults. As the population in the United States continues to age, nurses must be prepared to manage oncologic emergencies in older adults. Understanding the risk factors and preventive strategies for TLS provides oncology nurses with a foundation for managing a serious treatment complication. Patients and their caregivers need to understand the importance of preventive measures for TLS; therefore, patient education must be a critical part of the oncology nurse's plan of care.
Key foundational factors associated with successful nurse residency programs include a dedicated program coordinator, a healthy work environment, a structured curriculum guided by a theoretical framework, and an evaluation process that utilizes nurse resident feedback to improve the program (Chant & Westendorf, 2019). Furthermore, CCNE outlines key elements for demonstrating institutional fiscal commitment to support program educators, preceptors, and NTP nurses in fully participating in the program.
The Oncology Nursing Leadership Team at the Hospital of the University of Pennsylvania designed and implemented a phone consultation and intervention service to address increasing needs for specialty oncology nursing consultation and care for patients located on nononcology units. This article describes the planning, implementation, and evaluation of this service, which the team named the oncology phone. The service is available 24 hours per day, seven days per week by members of the Oncology Nursing Leadership Team and designated senior members of the clinical nursing staff. Consultation is initiated by any clinical nurse throughout the hospital who determines the need for oncology nursing expertise. Those needs include support for chemotherapy administration, symptom management, and care coordination. Data are collected from each call as well as subsequent face-to-face consultations and interventions. Evaluation of the data reveals important areas for education. A similar program may be valuable to other inpatient settings in addressing the needs of patients and staff.
A113 platelet production, resulting in low platelet counts (thrombocytopenia). Romiplostim has shown efficacy in increasing platelet counts. The objective of this study was to conduct meta-analysis and present total evidence for Romiplostim for treatment of ITP. METHODS: For this meta-analysis we included randomized controlled trials (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs that compared romiplostim versus placebo for management of ITP, had a treatment duration of at least 24 weeks, were doubleblind (patients and investigators blinded) and reported data on platelet response. A systematic literature search for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interventions, year, and the two outcomes overall and durable platelet response rate. For meta-analysis, random effects and fixed effects models were used to obtain cumulative statistics. RESULTS: Two RCTs with a total of 125 patients were identified. The pooled response rates for Romiplostim for overall platelet response rate were 82% (95% CI 73%-90%); and for durable platelet response rate were 48% (95% CI 26%-71%). The pooled response rates for placebo for overall platelet response rate were 7% (95% CI 0%-15%), and for durable platelet response rate were 2% (95% CI 0%-4%). For overall platelet response rate the cumulative relative risk with Romiplostim versus placebo was 0.09 (95% CI 4%-14%). For durable platelet response rate, the cumulative relative risk with Romiplostim versus placebo was 0.03 (95% CI 0%-6%). CONCLUSIONS: Meta-analysis shows Romiplostim offers patients with ITP an effective therapeutic option for increasing platelet counts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.